References
  1. Falhammar H, Lindh JD, Calissendorff J, Skov J, Nathanson D, Mannheimer B. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study. Eur J Intern Med . 2019;59:65-69.
  2. Han S, Kim J, Yim H, et al. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection. Antimicrob Agents Chemother . 2013;57(2):1006-1011.
  3. Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet . 1995;28(6):458-470.
  4. Bown RL. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. Int J Clin Pract . 2002;56(2):132-139.
  5. Vukićević T, Hinze C, Baltzer S, et al. Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking. J Am Soc Nephrol . 2019;30(5):795-810.